Publications
2026年度
論文・総説
・Mohri K, Nagai H, Mukozu T, Matsui T, Nagumo H, Yoshimine N, Kobayashi K, Ogino Y, Wakui N, Momiyama K, Higai K, Matsuda T, Igarashi Y. Clinical Utility of Tremelimumab/Durvalumab as First-line Treatment for Unresectable Hepatocellular Carcinoma: Serum Cytokine Profile Insights. Anticancer Res. 2026 Mar;46(3):1545-1556. doi: 10.21873/anticanres.18049.
2025年度
論文・総説
・Uekusa S, Nakashin M, Hanai Y, Nemoto M, Yanagino S, Arita Y, Matsumoto T, Wakui N, Nagai H, Higai K, Matsuo K.Risk factors for lenvatinib-induced hypertension in patients with hepatocellular carcinoma: A retrospective study. Br J Clin Pharmacol. 2025 Mar;91(3):894-902. doi: 10.1111/bcp.16337.
・Nagumo H, Nagai H, Higai K, Matsuda T, Igarashi Y. Effects of Atezolizumab plus Bevacizumab on Skeletal Muscle Volume and Cardiac Function in Patients with Hepatocellular Carcinoma.Oncology. 2025;103(5):369-379. doi: 10.1159/000541674.
・Mukozu T, Nagai H, Nagumo H, Mohri K, Yoshimine N, Kobayashi K, Ogino Y, Matsui T, Daido Y, Wakui N, Momiyama K, Higai K, Matsuda T, Igarashi Y. The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma.Oncology. 2025;103(4):277-289. doi: 10.1159/000541372.
・Kato A, Nihei W, Yako H, Tatsumi Y, Himeno T, Kondo M, Kato Y, Nakamura J, Kamiya H, Sango K, Kato K. Imeglimin improves hyperglycemia and hypoglycemia-induced cell death and mitochondrial dysfunction in immortalized adult mouse Schwann IMS32 cells. J Diabetes Investig. 2025 Sep;16(9):1586-1596. doi: 10.1111/jdi.70092.
2024年度
論文・総説
・Mohri K, Nagai H, Matsuda T, Igarashi Y, Higai K. Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab. Anticancer Res. 2024 Sep;44(9):3919-3929. doi: 10.21873/anticanres.17220.
・Uekusa S, Nemoto M, Hanai Y, Nakashin M, Yanagino S, Arita Y, Matsumoto T, Wakui N, Nagai H, Higai K, Matsuo K. Risk factors for lenvatinib-induced palmar-plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study. Cancer Med. 2024 Aug;13(16):e70065. doi: 10.1002/cam4.70065.
・Nagai H, Mukozu T, Matsui T, Mohri K, Nagumo H, Yoshimine N, Kobayashi K, Ogino Y, Daido Y, Wakui N, Momiyama K, Matsuda T, Igarashi Y, Higai K. Remaining Issues Related to Serum Cytokines in Patients with Unresectable Hepatocellular Carcinoma Treated by Atezolizumab plus Bevacizumab Combination Treatment. Oncology. 2024 doi: 10.1159/000537965.
・Tatsumi Y, Hayash H, Kato K. Comment to a patient with SLC40A1-HC successfully treated using red blood cell apheresis. Med Mol Morphol. 2024 Mar;57(1):82. doi: 10.1007/s00795-023-00375-8.
・Tatsumi Y, Yano M, Wakusawa S, Miyajima H, Ishikawa T, Imashuku S, Takano A, Nihei W, Kato A, Kato K, Hayashi H, Yoshioka K, Hayashi K. A Revised Classification of Primary Iron Overload Syndromes.
J Clin Transl Hepatol. 2024 Apr 28;12(4):346-356. doi: 10.14218/JCTH.2023.00290.
・Ishikawa T, Tatsumi Y, Kato K, Hayashi Y, Imai N, Ito T, Ishizu Y, Ishigami M, Nihei W, Kato A, Hayashi H. A 70-year-old Woman with Asymptomatic Ferroportin Disease. Intern Med. 2024 Sep 1;63(17):2421-2425. doi: 10.2169/internalmedicine.2392-23.
2023年度
論文・総説
・Kobayashi K., Nagai H., Matsui T., Matsuda T., Higai K. Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma. Anticancer Res. 2023;43(10):4601-4609. doi: 10.21873/anticanres.16654.
・Uekusa S., Nemoto M., Hanai Y., Nakashin M., Miyagawa A., Yanagino S., Arita Y., Matsumoto T., Nishizawa K., Nagai H., Higai K., Matsuo K. Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective Study. Pharmacology 2023;108(5):460-468. doi: 10.1159/000531881.
・Nagai H., Mukozu T., Kobayashi K., Nogami A., Nagumo H., Mohri K., Watanabe G., Amanuma M., Yoshimine N., Ogino Y., Matsui D., Daido Y., Matsukiyo Y., Matsui T., Wakui N., Momiyama K., Higai K., Matsuda T. Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma. Oncology. 2023;101(1):32-40. doi: 10.1159/000527306
・Nagai H., Amanuma M., Mukozu T., Kobayashi K., Nagumo H., Mohri K., Watanabe G., Yoshimine N., Ogino Y., Daido Y., Matsukiyo Y., Matsui T., Wakui N., Momiyama K., Higai K., Matsuda T., Igarashi Y. Effects of Lenvatinib on Skeletal Muscle Volume and Cardiac Function in Patients with Hepatocellular Carcinoma. Oncology. 2023;101(10):634-644. doi: 10.1159/000531562.
2022年度
論文・総説
・Mukozu T., Nagai H., Matsui D., Mohri K., Watanabe G.,Yoshimine N.,Amanuma M., Kobayashi K., Ogino Y., Matsukiyo Y., Matsui T., Daido Y., Wakui N., Shinohara M., Momiyama K., Higai K., Igarashi Y. Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis. Cancer Chemother Pharmacol. 89:11-20: 2022.
・Tatsumi Y., Kato A., Niimi N., Yako H., Himeno T., Kondo M., Tsunekawa S., Kato Y., Kamiya H., Nakamura J., Higai K., Sango K., Kato K. Docosahexaenoic acid suppresses oxidative stress-induced autophagy and cell death via the AMPK-dependent signaling pathway in the immortalized Fischer rat Schwann cells 1. International Journal of Molecular Sciences. 23:(8):4405: 2022.
2021年度
論文・総説
・Ohashi Y., Yatabe M., Niijima D.,Imamura A.,Nagayama Y.,Otsuka K., Yachi Y., Ueno H., Yano T., Mori N., Higai K., Yokoyama A. Importance of Compliance with Guidelines for the Prevention of Varicella-Zoster Virus Reactivation in Multiple Myeloma. in vivo. 35:(6):3289-3296: 2021.
・Zhang B., Liu D., Ji E., Otsuki K., Higai K., Zhao F., Li W., Koike K., Qiu F. Sacraoxides A-G, Bioactive Cembranoids from Gum Resin of Boswellia sacra. Front Chem. 9:649287: 2021.
2020年度
論文・総説
・Azuma Y, Suzuki K., Higai K., Matsumoto K.,Tada S: Biphasic Increases of Cell Surface Calreticulin Following Treatment with Mitoxantrone. Biol Pharm Bull. 43(10):1595-1599:2020.
・Kobayashi K., Higai K., Mukozu T., Matsui D., Amanuma M., Yoshimine N., Ogino Y., Matsui T., Wakui N., Shinohara M., Momiyama K., Daido Y.,, Nagai H., Igarashi Y. Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells. Biol. Pharm. Bull. 43, 1421–1425:2020.
・Ono M., Abe S., Higai K., Higashi S., Saito S.,Saito R. An improved and practical synthesis route toantiproliferative (±)-shikonin and its O-acylderivatives. Synthetic Communications 51(5), 738-746:2020.
・Ohashi Y., Yatabe M., Niijima D., Tani K., Ogawa C., Yachi Y., Kagoo T., Boku S., Ueno H., Yano T.,
Higai K., Yokoyama A. Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma. In Vivo 34(5):2821-2828: 2020.